Lincoln Pasquina

Clinical Development at @FoundationATCG

[Foundation Medicine @FoundationATCG]

Our team is excited to present two new pieces of research in #breastcancer that show the importance of robust homozygous gene loss reporting in BRCA1/2 and PTEN. Learn more from Foundation Medicine at #SABCS25 - booth 1342: https://t.co/l7EKz3sZc4

[Foundation Medicine @FoundationATCG]

Join us for an industry satellite symposium at #ESMOAsia25 “From Insights to Outcomes: How Comprehensive Genomic Profiling Redefines Cancer Care.” Learn more below!

Connect with our team at this year’s meeting: https://t.co/rR58kJ0MWL

[Foundation Medicine @FoundationATCG]

We’re in Chicago for #ASCO25 – come visit us at booth 27021 to learn more about Foundation Medicine. Schedule a meeting with us today: https://t.co/rV8hrNP91i #MissNotOne

[Charles Nguyen @charlesbnguyen]

Had a fun time presenting our poster at #ASCO2024 on #ctDNA in pts with #mHSPC!

Thanks to our pts, mentor @ReichertMedOnc, and @wandering_gu lab as well as @FoundationATCG for the collaboration! @lpasquina @RyonGraf

@GUOncologyNow @Uromigos @urotoday @UMRogelCancer

[Lincoln Pasquina @lpasquina]

@jacobadashek @targetcancer I am so glad to have the poster out there. It was great to see you!

[Foundation Medicine @FoundationATCG]

Meet us in Chicago! Find us at Booth 22031 to learn more about Foundation Medicine’s high-quality tests and our work in precision cancer care: https://t.co/6rbsBrY4U9 #ASCO24

[Christian Rolfo @ChristianRolfo]

Thanks @thenasheffect & @JCOPO_ASCO for the kind interview on our paper and great conversation!

@isliquidbiopsy
@TischCancer
@IcahnMountSinai
@Al3ssandroRusso @Marzia_DelRe
@geoff_oxnard
@lpasquina
@OncoAlert
@ASCOPost @ASCO

[Christian Rolfo @ChristianRolfo]

🚨Thanks ⁦⁦Dr Rafeq Naqash @thenasheffect⁩ for the kind invitation to ⁦@JCOPO_ASCO⁩ conversations podcast 🎤on our paper📝“Liquid Biopsy of Lung Cancer Before Path Diagnosis”⁦⁩ ⁦@Al3ssandroRusso⁩ ⁦@lpasquina⁩ ⁦@ASCO⁩ https://t.co/GLTbaE1MSU

[Christian Rolfo @ChristianRolfo]

Thanks to @myESMO ESMO Daily for highlighting our paper in @CCR_AACR Tumor Fraction #liquidbiopsy. This is an important concept to distinguish non shedders to non informative LB.
@lpasquina @HatimHusainMD
@TischCancer
Great comment by @UmbertoMalapel1
https://t.co/DM2zGeECsx

[Foundation Medicine @FoundationATCG]

Open now – a Call for Grants Notification, seeking collaborative projects & initiatives to address disparities in underserved breast or prostate cancer populations in the United States. Interested in applying? Click the link for more information: https://t.co/FDVFr5Y216

[Filippo Dall'Olio @FilippoDallOlio]

Liquid biopsy in head and neck cancers?
Let's discuss at #AACR2024!

[Foundation Medicine @FoundationATCG]

@CCR_AACR Excited to share this new research in collaboration with @ChristianRolfo et al. For more details on this research, click here: https://t.co/QTNCBCIMFA

[Foundation Medicine @FoundationATCG]

#NewStudy in @CCR_AACR evaluates circulating tumor DNA tumor fraction, a determination of ctDNA in liquid biopsy samples from Foundation Medicine’s blood-based comprehensive genomic profiling test, for its utility in identifying true negative results: https://t.co/QTNCBCIMFA

[JCO Precision Oncology @JCOPO_ASCO]

.@ChristianRolfo et al. demonstrate that early liquid biopsy in aNSCLC in parallel with path dx is associated with shorter time to treatment: https://t.co/nwb18YAWf3 #LCSM

[Alessandro Russo @Al3ssandroRusso]

A seminal paper in the liquid biopsy field by @ChristianRolfo and colleagues. ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. @CCR_AACR
@isliquidbiopsy @FoundationATCG

https://t.co/GiNdFPJWSg

[Foundation Medicine @FoundationATCG]

Newly #Published in the Journal of Liquid Biopsy – “Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases.” Read this piece of #research at the link: https://t.co/5YKAUfrVz0

[Lincoln Pasquina @lpasquina]

Just out in ESMO RWD: ctDNA tumor fraction from @FoundationATCG F1LCDx is associated with rwPFS and is prognostic across a range of TF cut points in metastatic urothelial carcinoma. With @BenMironMD @shilpaonc @RyonGraf @geoff_oxnard

https://t.co/7Jghac2O08

[Alessandro Russo @Al3ssandroRusso]

Liquid Biopsy (LBx) of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. Our analysis of a large database further reinforce the clinical utility of early LBx use in pts with suspected lung cancer. @ChristianRolfo @geoff_oxnard @lpasquina

[Aakash Desai @ADesaiMD]

🚨 In @isliquidbiopsy journal
"Putting comprehensive 🧬 profiling of ctDNA to work"
We explore ctDNA's utility across 4 categories:
1️⃣ Established 💊 selection
2️⃣ Emerging
3️⃣ Incidental discovery of secondary genomic findings
4️⃣ Quantification https://t.co/Nfq2DOxdBP

[Precision Medicine World Conference @PMWCintl]

Get ready for Session: Exploring the Clinical Utility of Dynamic #ctDNA Monitoring at #PMWC24. Join @lpasquina @FoundationATCG, @HatimHusainMD @UCSDHealth on 2024-01-24, Track: 3, 1.45 P.M. More at: https://t.co/uTYGt5hl6I